Medicare

organization

Last mentioned: Feb 24, 2026

Timeline

  1. Price Cut Effective

    Novo Nordisk's 50% list price reduction for Ozempic and Wegovy takes effect.

  2. Negotiation Deadline

    Expected announcement of final negotiated prices for the first round of Medicare drugs.

  3. Senate Hearing

    Novo Nordisk CEO Lars Fruergaard Jørgensen testifies on high U.S. drug prices.

  4. IRA Signed

    Inflation Reduction Act grants CMS authority to negotiate drug prices.

Stories mentioning Medicare 1

regulation Bullish

Novo Nordisk to Slash Ozempic and Wegovy List Prices by 50% in 2027

Novo Nordisk has announced a significant reduction in the list prices for its blockbuster GLP-1 drugs, Ozempic and Wegovy, effective in 2027. The move, which could see prices drop by up to 50%, comes amid intense political pressure and federal negotiations aimed at lowering healthcare costs for American consumers.

2 sources